Congress Democrats To Fight Medicare Misspending

9 December 1997

Fighting Medicare waste, fraud and abuse is one of CongressionalDemocrats' top priorities for 1998; it is estimated that the misspending costs $23 billion annually. Medicare is the theme for the first in a series of forums that Democrats are holding during Congress' recess.

Senate Democrat leader Tom Daschle has urged the bipartisan Medicare Commission to ferret out and address the waste and fraud before dealing with the true dimensions of long-term needs of Medicare. Senator Tom Harkin noted that while the bipartisan budget act approved last summer contained some anti-fraud measures, it is hoped these will be expanded in the coming year. Possible initiatives include tightening up on health care firms that declare bankruptcy to avoid repaying the government for improper billing, tighter requirements for doctors certifying home health programs and giving the Medicare program more resources to do audits and checks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight